Diabetic foot ulcers (DFUs) are a very common cause of mortality and morbidity. The distinction between infected and non-infected DFU remains a very challenging task for clinicians in everyday practice. Even when infection is documented, the spectrum of diabetic foot infection is wide, ranging from cellulitis and soft tissue infection to osteomyelitis. Procalcitonin (PCT), a well-established sepsis biomarker, has been used in the diagnosis of several infections including osteomyelitis in patients with diabetes mellitus. This review gathers and presents all the relevant data, up until now, regarding the use of PCT as an assessment tool in diabetic patients with foot infection. Current evidence suggests that PCT levels could aid clinicians in distinguishing infected from non-infected DFUs as well as in the distinction between soft tissue infection and bone involvement, but further and larger studies are warranted to confirm these findings.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. SINGH N ARMSTRONG DG LIPSKY BA. Preventing foot ulcers in patients with diabetes. JAMA 2005; 293:217–28.
2. GIURATO L MELONI M IZZO V et al. Osteomyelitis in diabetic foot: A comprehensive overview. World J. Diabetes 2017; 8:135–142.
3. LIPSKY BA BERENDT AR DEERY HG et al. Diagnosis and Treatment of Diabetic Foot Infections. Clin. Infect. Dis. 2004; 39:885–910.
4. SCHNEIDER H-G LAM QT. Procalcitonin for the clinical laboratory: a review. Pathology 2007; 39:383–90.
5. SCHUETZ P CHRIST-CRAIN M MÜLLER B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype? Swiss Med. Wkly. 2009; 139:318–26.
6. HAUSFATER P. Le dosage de la procalcitonine en pratique clinique chez l’adulte. La Rev. Médecine Interne 2007; 28:296–305.
7. DINH T SNYDER G VEVES A. Current techniques to detect foot infection in the diabetic patient. Int. J. Low. Extrem. Wounds 2010; 9:24–30.
8. GLAUDEMANS AWJM UÇKAY I LIPSKY BA. Challenges in diagnosing infection in the diabetic foot. Diabet. Med.2015; 32:748–59.
9. MASSARA M DE CARIDI G SERRA R et al. The role of procalcitonin as a marker of diabetic foot ulcer infection. Int. Wound J. 2017;14:31–34.
10. PICHU S PATEL BM APPARSUNDARAM S et al. Role of biomarkers in predicting diabetes complications with special reference to diabetic foot ulcers. Biomark. Med. 2017; 11:377–88.
11. VAN ASTEN SA NICHOLS A LA FONTAINE J et al. The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis. Int. Wound J. 2017; 14:40–45.
12. DELEVAUX I ANDRE M COLOMBIER M et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann. Rheum. Dis. 2003; 62:337–40.
13. SIMON L GAUVIN F AMRE DK et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin. Infect. Dis. 2004; 39:206–17.
14. CHRIST-CRAIN M MÜLLER B. Procalcitonin in bacterial infections--hype hope more or less? Swiss Med. Wkly. 2005; 135:451–60.
15. ASSICOT M GENDREL D CARSIN H et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet (London England) 1993; 341:515–8.
16. AL-SHAMMAREE SW ABU-ALKASEEM B SALMAN I. Procalcitonin levels and other biochemical parameters in patients with or without diabetic foot complications. J. Res. Med. Sci.2017; 22:95.
17. UMAPATHY D DORNADULA S RAJAGOPALAN A et al. Potential of circulatory procalcitonin as a biomarker reflecting inflammation among South Indian diabetic foot ulcers. J. Vasc. Surg. 2017; pii: S0741-5214 (17) 31127-8 (epub ahead of print).
18. INGRAM JR CAWLEY S COULMAN E et al. Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study).Diabet. Med.2017 doi: 10.1111/dme.13431 (epub ahead of print).
19. YANG Q CAO Y FANG Y et al. The influence of different debridement methods on the prognosis of elderly patients with diabetic foot ulcers and sepsis. Minerva Chir. 2017; 72:200–5.
20. PARK JH SUH DH KIM HJ et al. Role of procalcitonin in infected diabetic foot ulcer. Diabetes Res. Clin. Pract.2017; 128:51–7.
21. REINER MM KHOURY WE CANALES MB et al. Procalcitonin as a biomarker for predicting amputation level in lower extremity infections. J. Foot Ankle Surg. 2017; 56:484–91.
22. KARAKAS A ARSLAN E CAKMAK T et al. Predictive value of soluble CD14 Interleukin-6 and Procalcitonin for lower extremity amputation in people with diabetes with foot ulcers: A pilot study. Pakistan J. Med. Sci. 2014; 30:578–82.
23. JONAIDI JAFARI N SAFAEE FIROUZABADI M IZADI M et al. Can procalcitonin be an accurate diagnostic marker for the classification of diabetic foot ulcers? Int. J. Endocrinol. Metab. 2014; 12:e13376.
24. MICHAIL M JUDE E LIASKOS C et al. The performance of serum inflammatory markers for the diagnosis and follow-up of patients with osteomyelitis. Int. J. Low. Extrem. Wounds 2013; 12:94–9.
25. ALTAY FA SENCAN İ ŞENTÜRK GÇ et al. Does treatment affect the levels of serum interleukin-6 interleukin-8 and procalcitonin in diabetic foot infection? A pilot study. J. Diabetes Complications 2012; 26:214–8.
26. MUTLUOĞLU M UZUN G İPCIOGLU OM et al. Can procalcitonin predict bone infection in people with diabetes with infected foot ulcers? A pilot study. Diabetes Res. Clin. Pract. 2011; 94:53–6.
27. JEANDROT A RICHARD J-L COMBESCURE C et al. Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study. Diabetologia 2008; 51:347–52.
28. UZUN G SOLMAZGUL E CURUKSULU H et al. Procalcitonin as a diagnostic aid in diabetic foot infections. Tohoku J. Exp. Med 2007; 213:305–12.
29. VICTORIA VAN ASTEN SA GERADUS PETERS EJ XI Y et al. The role of biomarkers to diagnose diabetic foot osteomyelitis. A Meta-analysis. Curr. Diabetes Rev. 2016; 12:396–402.